检索范围:
排序: 展示方式:
null
《医学前沿(英文)》 2016年 第10卷 第2期 页码 204-211 doi: 10.1007/s11684-016-0443-1
CD176 (Thomsen-Friedenreich antigen) is a tumor-associated carbohydrate epitope (glycotope) functionally involved in blood spread and liver metastasis of cancer cells by mediating the adhesion of cancer cells to endothelial cells and hepatocytes, respectively. CD176 could be a promising target for antitumor immunotherapy. We applied B lymphocytes obtained from mice immunized with CD176 antigen and constructed a phage display library. A positive clone of CD176 single-chain variable antibody fragment (scFv) was successfully screened from this library. The CD176 scFv was expressed in Escherichia coli and purified. The purified scFv can bind to the natural CD176 expressed on the surface of cancer cells. Furthermore, the CD176 scFv inhibits the adhesion of CD176+ cancer cells to endothelial cells and hepatocytes. This CD176 scFv provides a basis for future development of recombinant CD176-specific antibodies that can be used in therapeutic application.
关键词: CD176 Thomsen-Friedenreich antigen scFv cancer therapy adhesion metastasis
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu, Jianhong Chu, Depei Wu
《医学前沿(英文)》 2020年 第14卷 第6期 页码 701-710 doi: 10.1007/s11684-020-0763-z
null
《医学前沿(英文)》 2013年 第7卷 第3期 页码 306-315 doi: 10.1007/s11684-013-0279-x
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective options for hematological malignancies, and human leukocyte antigen-partially matched related donors (PMRDs) are a valuable option for HSCT. Several protocols (with or without ex vivo T-cell depletion (TCD)) have been established worldwide. TCD including CD34+positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen disparity. However, TCD is associated with prolonged immune deficiencies, increased risks of infectious complications, and high transplantation-related mortality. PMRD HSCT without ex vivo TCD is well developed, and numerous patients have benefitted from it. Here, we review the literature on PMRD HSCT.
关键词: partially matched related donor hematopoietic stem cell transplantation allogeneic
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 711-725 doi: 10.1007/s11684-020-0808-3
关键词: chimeric antigen receptor T (CAR-T) cell lymphoma cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome (ICANS)
Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis
Shang-Long LIU, Zi-Fang SONG, Qing-Gang HU, Shao-Bo HU, Jun LI, Qi-Chang ZHENG, Duo SHAN,
《医学前沿(英文)》 2010年 第4卷 第4期 页码 457-462 doi: 10.1007/s11684-010-0240-1
关键词: cholangiocarcinoma prognostic factors serum carbohydrate antigen 19-9
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a
《医学前沿(英文)》 2022年 第16卷 第3期 页码 322-338 doi: 10.1007/s11684-021-0901-2
关键词: cancer immunotherapy chimeric antigen receptor solid tumors tumor-associated antigen glycosylation O-glycans adoptive cell therapy
Detection and monitoring prostate specific antigen using nanotechnology approaches to biosensing
Grant Perry, Fernando Cortezon-Tamarit, Sofia I. Pascu
《化学科学与工程前沿(英文)》 2020年 第14卷 第1期 页码 4-18 doi: 10.1007/s11705-019-1846-8
关键词: biosensing immunosensor PSA prostate cancer fluorescence
Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 786-791 doi: 10.1007/s11684-020-0751-3
关键词: anti-CD19 chimeric antigen receptor T cell soft tissue bone marrow relapsed or refractory non-Hodgkin lymphoma
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
《医学前沿(英文)》 2019年 第13卷 第1期 页码 57-68 doi: 10.1007/s11684-019-0683-y
Lung cancer is the most common incident cancer and the leading cause of cancer death. In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future. Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in various types of tumors and has been detected in non-small cell lung cancer with a mutation rate of 10%. Thus, EGFRvIII is a potential antigen for targeted lung cancer therapy. In this study, CAR vectors were constructed and transfected into virus-packaging cells. Then, activated T cells were infected with retrovirus harvested from stable virus-producing single clone cell lines. CAR expression on the surfaces of the T cells was detected by flow cytometry and Western blot. The function of CAR-T targeting EGFRvIII was then evaluated. The EGFRvIII-CAR vector was successfully constructed and confirmed by DNA sequencing. A stable virus-producing cell line was produced from a single clone by limited dilution. The culture conditions for the cell line, including cell density, temperature, and culture medium were optimized. After infection with retrovirus, CAR was expressed on more than 90% of the T cells. The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro. More importantly, EGFRvIII-CART specifically and efficiently recognized and killed A549-EGFRvIII cells with an effector/target ratio of 10:1 by expressing and releasing cytokines, including perforin, granzyme B, IFN-g, and TNF-α. The in vivo study indicated that the metastasis of A549-EGFRvIII cells in mice were inhibited by EGFRvIII-CART cells, and the survival of the mice was significantly prolonged with no serious side effects. EGFRvIII-CART showed significantly efficient antitumor activity against lung cancer cells expressing EGFRvIII in vivo and in vitro. Therefore, CAR-T targeting EGFRvIII is a potential therapeutic strategy in preventing recurrence and metastasis of lung cancer after surgery.
关键词: chimeric antigen receptor T cells epidermal growth factor receptor lung cancer immunotherapy tumor immunology
《医学前沿(英文)》 2022年 第16卷 第2期 页码 285-294 doi: 10.1007/s11684-021-0843-8
关键词: CAR-T cell therapy refractory diffuse large B-cell lymphoma cytokine release syndrome dose-limiting toxicity
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 811-815 doi: 10.1007/s11684-020-0740-6
关键词: anti-CD19 chimeric antigen receptor T cells mantle cell lymphoma relapsed or refractory long-term follow-up
Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of
《医学前沿(英文)》 doi: 10.1007/s11684-023-1010-1
关键词: exosomes induce activation impair function CD19 exosomal CD19 antigen
《医学前沿(英文)》 2023年 第17卷 第4期 页码 699-713 doi: 10.1007/s11684-022-0972-8
关键词: anti-CD19 chimeric antigen receptor T immunotherapy diffuse large B cell lymphoma tumor microenvironment tumor-associated macrophage metabolism
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 153-163 doi: 10.1007/s11684-017-0548-1
To establish optimal reference values for recovered immune cell subsets, we prospectively investigated post-transplant immune reconstitution (IR) in 144 patients who received allogeneic stem cell transplantation (allo-SCT) and without showing any of the following events: poor graft function, grades II?IV acute graft-versus-host disease (GVHD), serious chronic GVHD, serious bacterial infection, invasive fungal infection, or relapse or death in the first year after transplantation. IR was rapid in monocytes, intermediate in lymphocytes, CD3+ T cells, CD8+ T cells, and CD19+ B cells, and very slow in CD4+ T cells in the entire patient cohort. Immune recovery was generally faster under HLA-matched sibling donor transplantation than under haploidentical transplantation. Results suggest that patients with an IR comparable to the reference values display superior survival, and the levels of recovery in immune cells need not reach those in healthy donor in the first year after transplantation. We suggest that data from this recipient cohort should be used as reference values for post-transplant immune cell counts in patients receiving HSCT.
关键词: immune reconstitution hematopoietic stem cell transplantation event-free patients reference range
标题 作者 时间 类型 操作
CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes
null
期刊论文
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu, Jianhong Chu, Depei Wu
期刊论文
Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation
null
期刊论文
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
期刊论文
Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis
Shang-Long LIU, Zi-Fang SONG, Qing-Gang HU, Shao-Bo HU, Jun LI, Qi-Chang ZHENG, Duo SHAN,
期刊论文
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a
期刊论文
Detection and monitoring prostate specific antigen using nanotechnology approaches to biosensing
Grant Perry, Fernando Cortezon-Tamarit, Sofia I. Pascu
期刊论文
may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen
Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang
期刊论文
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
期刊论文
Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large
期刊论文
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
期刊论文
Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of
期刊论文
microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen
期刊论文